Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.00
Bid: 1,594.50
Ask: 1,595.50
Change: -19.00 (-1.17%)
Spread: 1.00 (0.063%)
Open: 1,608.00
High: 1,615.00
Low: 1,575.00
Prev. Close: 1,618.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Designer Daniel Lee replaces Riccardo Tisci at Burberry

Wed, 28th Sep 2022 09:44

Former Bottega Veneta creative head joins British brand

*

Tisci steps down after nearly five years

*

Move follows arrival of new CEO earlier this year

LONDON, Sept 28 (Reuters) - Burberry Group has appointed Daniel Lee as its new chief creative officer, replacing Riccardo Tisci, who is stepping down after presenting his final runway show for the British luxury brand on Monday.

The end of Tisci's near five-year tenure at Burberry follows the arrival of Jonathan Akeroyd as new chief executive earlier this year. Chief Financial Officier Julie Brown is also leaving to join drugmaker GSK.

Lee was creative director at Italy's Bottega Veneta from 2018 to 2021, and has previously worked at Celine, Maison Margiela, Balenciaga and Donna Karan, Burberry said on Wednesday.

The 35-year-old Central Saint Martins graduate successfully ignited the Italian label's popularity with younger consumers and boosted sales with popular accessories including pillowy leather clutch handbags and slip-on heels.

He departed suddenly from the Kering-owned brand last November, just three years into his position.

Lee, born in Yorkshire where Burberry manufactures its famous trench coats, said he was honoured to join the British fashion house and build on Tisci's legacy.

Shares in Burberry rose 3.2% in early deals on Wednesday, one of the few gainers in the FTSE 100 index which was 2% lower.

Stifel analyst Rogerio Fujimori said the change should be seen as a long-term positive given Lee's successful track record in ready-to-wear.

Luca Solca at Bernstein said Lee could develop product categories such as handbags and shoes.

"So far, the British brand has struggled to make its mark in these categories and create high profile iconic products," he said. "Daniel could open this opportunity."

However, the change could also increase the level of uncertainty and perceived lack of direction, following recent departures of the CEO and CFO and as the macroeconomic situation potentially deteriorates, said Thomas Chauvet of Citi.

Tisci was the creative force behind former chief executive Marco Gobbetti's strategy to elevate the position of the 166-year-old brand in the luxury sector.

His designs, many of which featured a new Thomas Burberry "TB" monogram, strengthened the brand's streetwear offer and attracted a younger and more diverse community of customers.

Stifel's Fujimori said his collections were however "not able to create the strong buzz seen at the hottest luxury brands in the past five years", such as Dior, YSL, Bottega Veneta and Balenciaga, which Burberry needed to accelerate top-line growth. (Reporting by Paul Sandle in London, Mimosa Spencer in Paris and Yadarisa Shabong in Bengaluru; Editing by Kate Holton, Sachin Ravikumar and Emelia Sithole-Matarise)

More News
20 Jun 2024 16:01

Industry groups back drugmakers' appeal in Zantac cancer lawsuits

June 20 (Reuters) - A bid by GSK and other drugmakers to stop more than 70,000 lawsuits in Delaware over discontinued heartburn drug Zantac has received the backing of leading U.S. industry groups, including the United States Chamber of Commerce and Pharmaceutical Research and Manufacturers of America.

Read more
11 Jun 2024 14:31

Zantac litigation fears overdone at GSK, says Shore Capital

(Sharecast News) - Volatile moves in GSK's share price are likely to persist in the near term as a result of ongoing Zantac-related litigation, but the long-term investment case is "still appealing", according to Shore Capital, which kept a 'buy' rating on the stock.

Read more
11 Jun 2024 09:32

TOP NEWS: GSK takes first steps to appeal Zantac ruling in Delaware

(Alliance News) - GSK PLC on Tuesday said it has taken the first steps to seek appeal of a ruling by the Delaware Superior Court in regard to its discontinued heartburn drug Zantac.

Read more
11 Jun 2024 09:12

LONDON MARKET OPEN: FTSE 100 up; UK unemployment rises to 4.4%

(Alliance News) - Stock prices in London opened higher on Tuesday, after a difficult day for markets on Monday amid the EU election fallout.

Read more
11 Jun 2024 07:52

LONDON BRIEFING: FTSE 100 called up despite unemployment rise

(Alliance News) - The FTSE 100 in London was called to open higher on Tuesday, after data showed that unemployment in the UK unexpectedly rose.

Read more
11 Jun 2024 07:22

GSK launches appeal to recent Zantac ruling

(Sharecast News) - GSK has started the process of appealing a recent decision by the Delaware Superior Court regarding the ongoing Zantac, or ranitidine, litigation, it announced on Tuesday.

Read more
11 Jun 2024 00:32

GSK asks to appeal Delaware ruling allowing Zantac cases to go forward

June 10 (Reuters) -

Read more
10 Jun 2024 22:49

Latest trial over Zantac cancer claims called off as plaintiff drops case

June 10 (Reuters) - A woman who claimed in a lawsuit that GSK's discontinued heartburn drug Zantac caused her breast cancer dropped her case shortly before it was set to go to trial in Illinois state court on Monday, the company announced.

Read more
10 Jun 2024 19:00

TOP NEWS: GSK welcomes dismissal of Zantac case in Illinois

(Alliance News) - GSK PLC on Monday welcomed the dismissal of a case in the US concerning the heartburn drug, Zantac, which was due to start on Monday.

Read more
10 Jun 2024 12:42

EU to secure 40 million avian flu vaccines for 15 countries - officials

BRUSSELS, June 10 (Reuters) - The EU will sign a contract on Tuesday to secure over 40 million doses of a preventative avian flu vaccine for 15 countries with the first shipments heading to Finland, EU officials said on Monday.

Read more
10 Jun 2024 08:39

GSK gets FDA approval for Arexvy vax in 50-59 year olds at risk of RSV

(Alliance News) - GSK PLC on Monday announced that the US Food & Drug Administration has approved an expanded age indication for its respiratory syncytial virus vaccine.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 07:17

GSK's Arexvy vaccine approved for wider age range

(Sharecast News) - US regulators have approved the use of GSK's Arexvy vaccine for a younger age group, the biopharma group announced on Monday.

Read more
7 Jun 2024 19:34

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, June 7 (Reuters) - The outbreak of bird flu in U.S. dairy cows has now been confirmed in Minnesota and Iowa, bringing to 11 the total number of affected states, which have been encouraged to ramp up testing efforts at the request of government officials.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.